Research and development

What we do

Medivir focuses on cancers of high unmet medical need, where existing therapies are not very successful and there is a great opportunity to provide real benefit to patients with few treatment options.

Who we are

Specialists in protease inhibitor design, and nucleoside- and nucleotide science. Medivir’s strategy is to apply our scientific expertise to the area of oncology to develop innovative anti-cancer drugs.

Why we do it

Cancer is the 2nd leading cause of death and more than 14 million new cases are diagnosed globally every year. This number is expected to increase in the future driven by the world’s growing and aging population.

Publications

Synergistic and additive anti-tumor effects of MIV-818 in combination with sorafenib in nonclinical hepatocellular carcinoma models

2018/04/17

Synergistic and additive anti-tumor effects of MIV-818 in combination with sorafenib in nonclinical hepatocellular carcinoma models

Presented at the annual meeting for the American Association for Cancer Research (AACR) in Chicago.

The selective cathepsin K inhibitor MIV‑711 attenuates joint pathology in experimental animal models of osteoarthritis

2018/03/19

The selective cathepsin K inhibitor MIV‑711 attenuates joint pathology in experimental animal models of osteoarthritis

Article published in Journal of Translational Medicine 2018.



How drug development works

Developing a new pharmaceutical is a long and resource-intensive process. It usually takes 10-15 years to bring a new drug to the shelves. Before a drug is deemed suitable for patients, it has to go through rigorous testing.